Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
American Journal of Ophthalmology, Volume 148, No. 2, Year 2009
Notification
URL copied to clipboard!
Description
Purpose: To assess the long-term role of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in inflammatory ocular neovascularization. Design: Retrospective multicenter consecutive case series of inflammatory ocular neovascularization. Methods: settings: Multicenter institutional and private practices. study population: Patients with inflammatory ocular neovascularization in one or both eyes of varying etiologies who failed standard therapy. intervention: Intravitreal injection of bevacizumab. main outcome measures: Improvement of best-corrected visual acuity (BCVA) expressed as logarithm of minimal angle of resolution (logMAR), and decrease in central foveal thickness as measured by optical coherence tomography at 6, 12, 18, and 24 months of follow-up. Results: Mean logMAR BCVA (central foveal thickness) following intravitreal bevacizumab was as follows: baseline, 0.65 (6/27 or 20/90) (338 μm; 99 eyes of 96 patients); 6 months, 0.42 (6/16 or 20/53) (239 μm; 2.0 injections; 81 eyes); 12 months, 0.39 (6/15 or 20/49) (241 μm; 2.3 injections; 95 eyes); 18 months, 0.40 (6/15 or 20/50) (261 μm; 3.0 injections; 46 eyes); and 24 months, 0.34 (6/13 or 20/44) (265 μm; 3.6 injections; 27 eyes). Paired comparisons revealed significant visual improvement at 6 months of 2.4 lines (P = .000), at 12 months of 2.5 lines (P = .000), at 18 months of 2.5 lines (P = .001), and at 24 months of 2.2 lines (P = .013). Paired comparisons revealed significant central foveal flattening at 6 months of 78 μm (P = .000), at 12 months of 85 μm (P = .000), at 18 months of 90 μm (P = .003), and at 24 months of 77 μm (P = .022). Three eyes developed submacular fibrosis and 1 eye submacular hemorrhage. Conclusion: Intravitreal bevacizumab led in the long-term to significant mean visual improvement of ≥2.2 lines and significant foveal flattening in a wide variety of inflammatory ocular diseases without major complications. © 2009 Elsevier Inc. All rights reserved.
Authors & Co-Authors
Mansour, Ahmad M.
Lebanon, Beirut
American University of Beirut
Lebanon, Beirut
Rafik Hariri University Hospital
Arévalo, José Fernando
Venezuela, Merida
Universidad de Los Andes, Merida
Ziemssen, Focke
Germany, Tubingen
Eberhard Karls Universität Tübingen
Mehio-Sibai, Abla
Lebanon, Beirut
American University of Beirut
Mackensen, Friederike
Germany, Heidelberg
Universität Heidelberg
Adán, Alfredo Manuel
Spain, Barcelona
Universitat de Barcelona
Chan, Waiman
Hong Kong, Hong Kong
Chinese University of Hong Kong
Ness, Thomas
Germany, Freiburg Im Breisgau
Universitätsklinikum Freiburg
Banker, Alay
India, Ahmedabad
Laser Centre
Dodwell, David
United States, Springfield
Springfield Eye Clinic
Chau Tran, Thi Ha
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Fardeau, Christine
France, Paris
Hôpital Universitaire Pitié Salpêtrière
LeHoang, Phuc
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Mahendradas, Padmamalini
India, Bangalore
Departments of Uveitis and Retina
Berrocal, María H.
Puerto Rico, San Juan
Universidad de Puerto Rico
Tabbarah, Z. A.
Lebanon, Beirut
American University of Beirut
Lebanon, Beirut
Rafik Hariri University Hospital
Hrisomalos, Nicholas
United States, Indianapolis
Indiana University-purdue University Indianapolis
Hrisomalos, Frank N.
United States, Indianapolis
Indiana University-purdue University Indianapolis
al-Salem, Khalil Mahmoud
Lebanon, Beirut
American University of Beirut
Guthoff, Rainer
Germany, Wurzburg
Julius-maximilians-universität Würzburg
Statistics
Citations: 72
Authors: 20
Affiliations: 15
Identifiers
Doi:
10.1016/j.ajo.2009.03.023
ISSN:
00029394
Research Areas
Health System And Policy
Study Design
Randomised Control Trial
Cross Sectional Study
Cohort Study